| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 20 | 2025 | 307 | 5.070 |
Why?
|
| Septal Occluder Device | 18 | 2026 | 52 | 4.410 |
Why?
|
| Heart-Assist Devices | 11 | 2018 | 916 | 2.440 |
Why?
|
| Shock, Cardiogenic | 6 | 2024 | 183 | 2.200 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2025 | 194 | 2.150 |
Why?
|
| Heart Arrest | 14 | 2024 | 315 | 2.030 |
Why?
|
| Foramen Ovale, Patent | 3 | 2025 | 23 | 1.910 |
Why?
|
| Echocardiography, Transesophageal | 15 | 2025 | 266 | 1.860 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2017 | 133 | 1.860 |
Why?
|
| Atrial Appendage | 6 | 2025 | 45 | 1.770 |
Why?
|
| Myocardial Infarction | 12 | 2024 | 396 | 1.760 |
Why?
|
| Cardiopulmonary Resuscitation | 10 | 2024 | 256 | 1.730 |
Why?
|
| Ventricular Fibrillation | 10 | 2016 | 73 | 1.680 |
Why?
|
| Myocardial Ischemia | 8 | 2024 | 142 | 1.650 |
Why?
|
| Aortic Valve | 6 | 2026 | 258 | 1.600 |
Why?
|
| Aortic Valve Stenosis | 7 | 2026 | 155 | 1.580 |
Why?
|
| Ventricular Function, Left | 9 | 2021 | 540 | 1.560 |
Why?
|
| Heart Valve Prosthesis Implantation | 7 | 2023 | 192 | 1.560 |
Why?
|
| Atrial Fibrillation | 8 | 2026 | 460 | 1.530 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2024 | 230 | 1.460 |
Why?
|
| Absorbable Implants | 4 | 2021 | 38 | 1.400 |
Why?
|
| Coronary Vessels | 8 | 2024 | 178 | 1.370 |
Why?
|
| Treatment Outcome | 45 | 2026 | 9682 | 1.370 |
Why?
|
| Heart Septal Defects, Ventricular | 3 | 2019 | 66 | 1.340 |
Why?
|
| Coronary Angiography | 17 | 2024 | 237 | 1.320 |
Why?
|
| Popliteal Artery | 3 | 2021 | 32 | 1.290 |
Why?
|
| Peripheral Arterial Disease | 3 | 2021 | 110 | 1.260 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 91 | 1.200 |
Why?
|
| Heart Failure | 9 | 2021 | 1491 | 1.140 |
Why?
|
| Ischemia | 2 | 2020 | 262 | 1.080 |
Why?
|
| Prosthesis Design | 13 | 2026 | 308 | 1.070 |
Why?
|
| Ultrasonography, Interventional | 4 | 2025 | 126 | 1.060 |
Why?
|
| Coronary Artery Disease | 8 | 2024 | 387 | 1.050 |
Why?
|
| Thrombosis | 4 | 2025 | 318 | 1.030 |
Why?
|
| Percutaneous Coronary Intervention | 7 | 2020 | 81 | 1.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 9 | 2012 | 66 | 0.980 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2024 | 508 | 0.970 |
Why?
|
| Echocardiography, Three-Dimensional | 8 | 2020 | 339 | 0.960 |
Why?
|
| Registries | 11 | 2026 | 1120 | 0.930 |
Why?
|
| Male | 68 | 2026 | 46992 | 0.920 |
Why?
|
| Endothelin-1 | 3 | 2011 | 42 | 0.900 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2025 | 61 | 0.900 |
Why?
|
| Transcatheter Aortic Valve Replacement | 3 | 2026 | 79 | 0.880 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1108 | 0.870 |
Why?
|
| Humans | 93 | 2026 | 97883 | 0.870 |
Why?
|
| Anticoagulants | 3 | 2025 | 483 | 0.850 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 4 | 2020 | 109 | 0.840 |
Why?
|
| Aged | 39 | 2026 | 21702 | 0.820 |
Why?
|
| Middle Aged | 40 | 2026 | 29353 | 0.820 |
Why?
|
| Stents | 5 | 2024 | 433 | 0.810 |
Why?
|
| Hemodynamics | 7 | 2026 | 745 | 0.790 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 94 | 0.760 |
Why?
|
| Time Factors | 17 | 2026 | 5555 | 0.760 |
Why?
|
| Retrospective Studies | 28 | 2026 | 10947 | 0.740 |
Why?
|
| Catheterization | 5 | 2017 | 219 | 0.730 |
Why?
|
| Pulmonary Embolism | 6 | 2021 | 234 | 0.730 |
Why?
|
| Female | 54 | 2026 | 51464 | 0.700 |
Why?
|
| Thrombolytic Therapy | 5 | 2021 | 259 | 0.670 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 236 | 0.660 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 398 | 0.630 |
Why?
|
| Heart Diseases | 5 | 2021 | 268 | 0.620 |
Why?
|
| Risk Assessment | 14 | 2026 | 2580 | 0.620 |
Why?
|
| Secondary Prevention | 1 | 2021 | 185 | 0.620 |
Why?
|
| Electrocardiography | 6 | 2021 | 527 | 0.610 |
Why?
|
| Heart Ventricles | 4 | 2020 | 664 | 0.590 |
Why?
|
| Coronary Artery Bypass | 4 | 2023 | 231 | 0.590 |
Why?
|
| Aged, 80 and over | 15 | 2026 | 7386 | 0.540 |
Why?
|
| Hospital Costs | 1 | 2019 | 117 | 0.540 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 31 | 0.530 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 54 | 0.530 |
Why?
|
| Mitral Valve | 6 | 2020 | 229 | 0.530 |
Why?
|
| Clinical Protocols | 1 | 2018 | 156 | 0.520 |
Why?
|
| Swine | 14 | 2016 | 591 | 0.520 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 43 | 0.520 |
Why?
|
| Balloon Occlusion | 3 | 2012 | 29 | 0.520 |
Why?
|
| Prosthesis Failure | 2 | 2017 | 117 | 0.510 |
Why?
|
| Blood Circulation | 1 | 2017 | 29 | 0.510 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 134 | 0.510 |
Why?
|
| Heart Massage | 1 | 2017 | 11 | 0.510 |
Why?
|
| Venae Cavae | 1 | 2017 | 12 | 0.510 |
Why?
|
| Arteriovenous Fistula | 1 | 2018 | 57 | 0.510 |
Why?
|
| Transposition of Great Vessels | 1 | 2017 | 24 | 0.510 |
Why?
|
| Device Removal | 1 | 2018 | 170 | 0.510 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 187 | 0.500 |
Why?
|
| Aminophylline | 1 | 2016 | 13 | 0.500 |
Why?
|
| Stroke | 4 | 2026 | 1154 | 0.490 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 28 | 0.490 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 242 | 0.480 |
Why?
|
| Bradycardia | 1 | 2016 | 51 | 0.480 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 210 | 0.480 |
Why?
|
| Dyspnea | 1 | 2016 | 90 | 0.470 |
Why?
|
| Balloon Valvuloplasty | 1 | 2015 | 9 | 0.460 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 34 | 0.460 |
Why?
|
| Vascular Fistula | 1 | 2015 | 12 | 0.450 |
Why?
|
| Cardiomyopathies | 2 | 2018 | 315 | 0.450 |
Why?
|
| Disease Management | 1 | 2018 | 377 | 0.450 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2020 | 179 | 0.450 |
Why?
|
| Risk Factors | 14 | 2026 | 6224 | 0.450 |
Why?
|
| Fontan Procedure | 1 | 2015 | 58 | 0.440 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 121 | 0.440 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 190 | 0.430 |
Why?
|
| Postoperative Complications | 3 | 2017 | 2680 | 0.430 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2020 | 161 | 0.430 |
Why?
|
| Ventricular Septum | 1 | 2014 | 15 | 0.430 |
Why?
|
| Heart Injuries | 1 | 2014 | 23 | 0.420 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 70 | 0.420 |
Why?
|
| Epinephrine | 2 | 2011 | 91 | 0.410 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 4023 | 0.400 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 118 | 0.400 |
Why?
|
| Aneurysm, False | 1 | 2014 | 52 | 0.400 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2015 | 75 | 0.400 |
Why?
|
| Adenosine | 1 | 2016 | 291 | 0.390 |
Why?
|
| Heart Valve Prosthesis | 3 | 2026 | 97 | 0.390 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 101 | 0.370 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 368 | 0.360 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 316 | 0.350 |
Why?
|
| Biomarkers | 4 | 2019 | 2016 | 0.350 |
Why?
|
| Vascular Patency | 3 | 2021 | 123 | 0.350 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 180 | 0.340 |
Why?
|
| Thymosin | 1 | 2011 | 6 | 0.340 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 15 | 0.330 |
Why?
|
| Adult | 15 | 2025 | 29453 | 0.330 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 72 | 0.330 |
Why?
|
| Predictive Value of Tests | 8 | 2025 | 1778 | 0.320 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 67 | 0.320 |
Why?
|
| Electric Countershock | 2 | 2011 | 77 | 0.320 |
Why?
|
| Coronary Disease | 2 | 2012 | 227 | 0.320 |
Why?
|
| Ventricular Pressure | 3 | 2021 | 41 | 0.310 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 2008 | 0.310 |
Why?
|
| Myocarditis | 1 | 2010 | 60 | 0.310 |
Why?
|
| Coronary Thrombosis | 2 | 2017 | 15 | 0.300 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 204 | 0.300 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 194 | 0.300 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 2571 | 0.300 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 252 | 0.290 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 24 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 400 | 0.290 |
Why?
|
| After-Hours Care | 1 | 2008 | 8 | 0.290 |
Why?
|
| Heart Rate | 2 | 2010 | 534 | 0.280 |
Why?
|
| United States | 9 | 2026 | 8184 | 0.280 |
Why?
|
| Medical Errors | 1 | 2008 | 93 | 0.270 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 11 | 0.260 |
Why?
|
| Fish Oils | 1 | 2007 | 15 | 0.260 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2007 | 22 | 0.260 |
Why?
|
| Coronary Circulation | 3 | 2024 | 97 | 0.260 |
Why?
|
| Vasodilation | 1 | 2007 | 91 | 0.260 |
Why?
|
| Docosahexaenoic Acids | 1 | 2007 | 35 | 0.250 |
Why?
|
| Hypoxia | 1 | 2012 | 681 | 0.250 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 295 | 0.240 |
Why?
|
| Hemorrhage | 2 | 2025 | 297 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 228 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2025 | 38 | 0.230 |
Why?
|
| Artifacts | 1 | 2007 | 248 | 0.230 |
Why?
|
| Thrombectomy | 1 | 2008 | 260 | 0.220 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 440 | 0.220 |
Why?
|
| Saphenous Vein | 3 | 2010 | 61 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 403 | 0.220 |
Why?
|
| Ultrasonography | 4 | 2015 | 720 | 0.210 |
Why?
|
| Stroke Volume | 5 | 2021 | 464 | 0.210 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 337 | 0.210 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 56 | 0.210 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 92 | 0.210 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 100 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 523 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 532 | 0.200 |
Why?
|
| Administration, Oral | 1 | 2025 | 674 | 0.200 |
Why?
|
| Carotid Arteries | 1 | 2024 | 132 | 0.200 |
Why?
|
| Recovery of Function | 3 | 2026 | 370 | 0.190 |
Why?
|
| Cysteine | 1 | 2024 | 149 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2024 | 119 | 0.190 |
Why?
|
| Clinical Competence | 1 | 2008 | 863 | 0.190 |
Why?
|
| Osteosarcoma | 1 | 2003 | 157 | 0.190 |
Why?
|
| Heart Transplantation | 2 | 2023 | 873 | 0.180 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 342 | 0.180 |
Why?
|
| Microcirculation | 2 | 2024 | 101 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1416 | 0.180 |
Why?
|
| Coronary Restenosis | 4 | 2017 | 13 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 707 | 0.180 |
Why?
|
| Ulnar Artery | 1 | 2022 | 8 | 0.180 |
Why?
|
| Survival Rate | 5 | 2019 | 2040 | 0.180 |
Why?
|
| Echocardiography | 5 | 2020 | 783 | 0.180 |
Why?
|
| Radial Artery | 1 | 2022 | 41 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2024 | 799 | 0.170 |
Why?
|
| Aorta | 2 | 2020 | 275 | 0.170 |
Why?
|
| Hospitals | 2 | 2021 | 335 | 0.170 |
Why?
|
| Heart Atria | 3 | 2016 | 255 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 802 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 316 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 2019 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2024 | 968 | 0.170 |
Why?
|
| Everolimus | 1 | 2021 | 35 | 0.160 |
Why?
|
| Acute Disease | 3 | 2021 | 857 | 0.160 |
Why?
|
| Transillumination | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cardiology | 1 | 2021 | 124 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2017 | 2666 | 0.160 |
Why?
|
| Limb Salvage | 1 | 2020 | 43 | 0.160 |
Why?
|
| Prognosis | 5 | 2024 | 4112 | 0.150 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2010 | 92 | 0.150 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 17 | 0.150 |
Why?
|
| Reoperation | 2 | 2013 | 727 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 85 | 0.150 |
Why?
|
| Mobile Applications | 1 | 2021 | 83 | 0.150 |
Why?
|
| Animals | 15 | 2016 | 28899 | 0.150 |
Why?
|
| Resuscitation | 2 | 2011 | 134 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 195 | 0.150 |
Why?
|
| Heart | 3 | 2020 | 527 | 0.150 |
Why?
|
| Health Equity | 1 | 2021 | 116 | 0.140 |
Why?
|
| Fluoroscopy | 1 | 2019 | 138 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 264 | 0.140 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 2783 | 0.140 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2018 | 14 | 0.140 |
Why?
|
| Atrial Function, Left | 1 | 2018 | 37 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 166 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 219 | 0.130 |
Why?
|
| Microvessels | 1 | 2018 | 70 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 299 | 0.130 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Recurrence | 2 | 2012 | 1254 | 0.130 |
Why?
|
| Communication | 1 | 2021 | 455 | 0.130 |
Why?
|
| Blood Pressure | 3 | 2013 | 909 | 0.130 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 6 | 0.130 |
Why?
|
| Echocardiography, Doppler | 1 | 2017 | 137 | 0.130 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.120 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 11 | 0.120 |
Why?
|
| Tumor Necrosis Factors | 1 | 2016 | 14 | 0.120 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 32 | 0.120 |
Why?
|
| Triage | 1 | 2018 | 151 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2019 | 1094 | 0.120 |
Why?
|
| Bioprosthesis | 1 | 2016 | 42 | 0.120 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 309 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 166 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 194 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 985 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 264 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2016 | 119 | 0.120 |
Why?
|
| Cannula | 1 | 2016 | 55 | 0.120 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 92 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 619 | 0.120 |
Why?
|
| Macrophages | 1 | 2019 | 643 | 0.110 |
Why?
|
| Subclavian Artery | 1 | 2015 | 43 | 0.110 |
Why?
|
| Length of Stay | 1 | 2019 | 869 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2018 | 4798 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2016 | 295 | 0.100 |
Why?
|
| Random Allocation | 4 | 2020 | 311 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 360 | 0.100 |
Why?
|
| Comorbidity | 2 | 2015 | 1032 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 77 | 0.100 |
Why?
|
| Aortography | 1 | 2014 | 60 | 0.100 |
Why?
|
| California | 3 | 2010 | 169 | 0.100 |
Why?
|
| Contrast Media | 1 | 2018 | 1011 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 18 | 0.100 |
Why?
|
| Kidney | 1 | 2018 | 1121 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3606 | 0.100 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 47 | 0.100 |
Why?
|
| Amiodarone | 1 | 2013 | 16 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1567 | 0.100 |
Why?
|
| Dobutamine | 1 | 2013 | 38 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 71 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 38 | 0.100 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 50 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 77 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 642 | 0.090 |
Why?
|
| Software | 1 | 2017 | 692 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2016 | 1527 | 0.090 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 123 | 0.090 |
Why?
|
| Exercise Test | 1 | 2013 | 158 | 0.090 |
Why?
|
| Algorithms | 2 | 2017 | 2000 | 0.090 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2012 | 7 | 0.090 |
Why?
|
| Mitral Valve Stenosis | 1 | 2012 | 27 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 268 | 0.090 |
Why?
|
| Labetalol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Metoprolol | 1 | 2011 | 16 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2014 | 318 | 0.090 |
Why?
|
| Vascular Resistance | 2 | 2024 | 98 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 155 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 111 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2015 | 381 | 0.080 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 28 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 155 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 480 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 254 | 0.080 |
Why?
|
| Catheters | 2 | 2021 | 109 | 0.080 |
Why?
|
| Vasopressins | 1 | 2010 | 48 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2026 | 518 | 0.080 |
Why?
|
| Creatine Kinase | 1 | 2010 | 51 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 983 | 0.080 |
Why?
|
| Infliximab | 4 | 2013 | 166 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 94 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 263 | 0.080 |
Why?
|
| Troponin | 1 | 2010 | 25 | 0.080 |
Why?
|
| Proteinuria | 1 | 2010 | 72 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 108 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2010 | 95 | 0.080 |
Why?
|
| Patient Selection | 3 | 2020 | 720 | 0.080 |
Why?
|
| Coronary Sinus | 1 | 2010 | 11 | 0.080 |
Why?
|
| Myocardium | 2 | 2010 | 578 | 0.080 |
Why?
|
| Critical Illness | 1 | 2012 | 360 | 0.070 |
Why?
|
| Sirolimus | 1 | 2010 | 182 | 0.070 |
Why?
|
| Endothelin-2 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Endothelin-3 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2010 | 340 | 0.070 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 14 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1944 | 0.070 |
Why?
|
| Paclitaxel | 1 | 2010 | 483 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 148 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2011 | 743 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 382 | 0.070 |
Why?
|
| Chicago | 1 | 2013 | 1513 | 0.070 |
Why?
|
| Diastole | 2 | 2018 | 101 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 130 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 187 | 0.070 |
Why?
|
| Nitroglycerin | 1 | 2007 | 24 | 0.070 |
Why?
|
| Vitamin E | 1 | 2007 | 34 | 0.070 |
Why?
|
| Selection Bias | 1 | 2007 | 37 | 0.070 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 103 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2007 | 159 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2007 | 201 | 0.060 |
Why?
|
| Cell Movement | 1 | 2011 | 815 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2008 | 249 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 164 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2007 | 152 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 158 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 32 | 0.060 |
Why?
|
| Observer Variation | 1 | 2007 | 579 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 31 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 889 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1013 | 0.060 |
Why?
|
| Metals | 1 | 2005 | 104 | 0.050 |
Why?
|
| Action Potentials | 1 | 2008 | 611 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1646 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 601 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 151 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2024 | 299 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 684 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 246 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 234 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 7504 | 0.050 |
Why?
|
| Spasm | 1 | 2022 | 17 | 0.040 |
Why?
|
| Preoperative Care | 2 | 2015 | 418 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1995 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 108 | 0.040 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2020 | 142 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 359 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 370 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 581 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1384 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 30 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 724 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 920 | 0.030 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 95 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 484 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 81 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 425 | 0.030 |
Why?
|
| Apoptosis | 1 | 2003 | 1752 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 358 | 0.030 |
Why?
|
| Phlebography | 1 | 2017 | 74 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 522 | 0.030 |
Why?
|
| Oxygen | 1 | 2021 | 772 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 385 | 0.030 |
Why?
|
| Quality of Life | 1 | 2004 | 1891 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 282 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 539 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 304 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 478 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 345 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 503 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 11 | 0.030 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2013 | 5 | 0.020 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 21 | 0.020 |
Why?
|
| Lidocaine | 1 | 2013 | 62 | 0.020 |
Why?
|
| Etanercept | 1 | 2013 | 37 | 0.020 |
Why?
|
| Heart Arrest, Induced | 1 | 2013 | 30 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 85 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 198 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 161 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 133 | 0.020 |
Why?
|
| Reference Values | 1 | 2013 | 608 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2011 | 49 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 221 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 301 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2010 | 3 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 658 | 0.020 |
Why?
|
| Adolescent | 1 | 2003 | 10078 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 92 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 312 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 164 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2008 | 6 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 279 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1960 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 214 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 902 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 1193 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1121 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 214 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 1137 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2006 | 47 | 0.010 |
Why?
|
| Collagen | 1 | 2006 | 313 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 286 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 889 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2003 | 25 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 32 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2003 | 61 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 148 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 462 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 581 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1776 | 0.010 |
Why?
|